{"id":"cxa-201","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tendinopathy"}]},"_chembl":{"chemblId":"CHEMBL561371","moleculeType":"Small molecule","molecularWeight":"327.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CXA-201 is a fluoroquinolone-class antibiotic developed to treat serious gram-negative bacterial infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and cell division, thereby preventing bacterial growth and survival.","oneSentence":"CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:11.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI)"},{"name":"Acute bacterial cystitis"},{"name":"Gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT01445678","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-12-23","conditions":"Complicated Intra-abdominal Infection","enrollment":494},{"nctId":"NCT01345929","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-06-20","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":558}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CXA-201","genericName":"CXA-201","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome. Used for Complicated urinary tract infections (cUTI), Acute bacterial cystitis, Gram-negative bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}